Home » Amgen, Array BioPharma Enter Development Agreement

Amgen, Array BioPharma Enter Development Agreement

December 15, 2009

Biotech drug developer Amgen Inc. has entered an agreement with Array BioPharma Inc. to develop a potential treatment for type 2 diabetes, the companies said.
TheStreet

10Mar
FDA Drug GMP Facility Inspections During the Pandemic
16Mar
Pharmaceutical Naming Regulation: Understanding the Latest Developments
18Mar
Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19
23Mar
Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges
30Mar
Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges
06Apr
Medical Device Cybersecurity: Understand the Latest Developments

Amgen, Array BioPharma Enter Development Agreement

Upcoming Events

FDA Drug GMP Facility Inspections During the Pandemic

Pharmaceutical Naming Regulation: Understanding the Latest Developments

Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

Biological Risk Evaluation and Management for Medical Devices

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

Sanofi’s and Regeneron’s Libtayo Wins FDA Approval for NSCLC

PerkinElmer’s Rapid Point-of-Care COVID-19 Test Cleared in Europe

President Biden Issues Executive Order on U.S. Supply Chain

Priority Healthcare Settles Diabetes Test Lawsuit with Roche for $43 Million

The Revised ICH E8: A Guide to New Clinical Trial Requirements